Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and safety of biologic therapies for inducing and maintaining remission in Crohn's disease.
Conducted a network meta-analysis of 94 randomised controlled trials (N=20,653 for induction, N=6,823 for maintenance).
Outcomes expressed as risk ratios with 95% confidence intervals.
Assessment of risk of bias and grading of evidence certainty using Cochrane and GRADE.
Ustekinumab demonstrated high-certainty evidence with RR 2.01 for inducing clinical remission.
Adalimumab proved moderately effective for maintenance with RR 0.69 preventing relapse.
Evidence for several biologics remained of low certainty with indeterminate conclusions.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Network meta-analysis assesses biologic therapies for remission in Crohn's disease, suggesting evidence for treatment choices.

No takes yet. Share an insight, caveat, or question.

Gordon et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share